NUESTROS AUTORES
Mezquita P, Muños M, Luna JD, et al. Relation between vitamin D insufficiency, bone density and bone metabolism in healthy postmenopausal women. J Bone Miner Res 2001; 16: 1408-15.
Blay P, Fernández-Martínez JM, Díaz-López B. Vertebral involvement in hyperphosphatemic tumoral calcinosis. Bone 2001; 28: 316-8.
Espallargues M, Sampietro L, Estrada MD, et al. Identifying bone-mass-relatd risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature.
Se ruega a los autores enviar una copia del trabajo para incluir su cita en esta Sección.
REVISIONES
Jerome CP, Peterson PE. Nonhuman primate models in skeletal research. Bone 2001; 29: 1-6.
Lyes KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget´s disease of bone. J Bone Miner Res 2001; 16: 1379-87.
Parfitt AM. The bone remodeling compartment: a circulatory function for bone lining cells. J Bone Miner Res 2001; 16: 1583-5.
Melton LJ, Orwoll ES, Wasnich RD. Does bone density predict fractures comparably in men and women? Osteoporosis Int 2001; 12: 707-9.
Lanyon L, Skerry T. Postmenopausal osteoporosis as a failure of bone´s adaptation to functional loading: A hypothesis. J Bone Miner Res 2001; 16: 1937-47.
Raisz LG, Seeman E. Cuases of age-related bone loss and bone fragility: An alterantive view. J Bone Miner Res 2001; 16: 1948-52.
Parfitt AM. The bone remodeling compartment: A circulatory function for bone lining cells. J Bone Miner Res 2001; 16: 1583-5.
Blank RD. Breaking down bone strength: a peerspective on the future of skeletal genetics. J Bone Miner Res 2001; 16: 1206-11.
Zaidi M, Troen B, Moogan BS, Abe E. Catepsin K, osteoclastic resorption and osteoporosis therapy. J Bone Miner Res 2001; 16: 1747-9.
Meulen MCH, Jepsen KJ, Mikic B. Understanding bone strength: Size isn´t everything. Bone 2001; 29: 101-4.
Rosen CJ, Beamer WG, Donahue LR. Defining the genetics of osteoporosis: Using the mouse to undestand man. Osteoporosis Int 2001; 12: 803-10.
Olgaard K, Lewin E. Prevention of uremic bone disease using calcimietic compounds. Ann Rev Med 2001; 52:203-220
Nilsson S, Makala S, Treuer E, et al. Mechanisms of estrogen action. Physiol Rev 2001; 81:1536-65.
Tordoff MG. Calcium: Taste, intake and appetite. Physiol Rev 2001; 81: 1567-97.
OTROS ARTÍCULOS DE INTERÉS
Wehrli FW, Gombreg BR, Saha PK, et al. Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis. J Bone Miner Res 2001; 16: 1520-31.
Szulc P, Garnero P, Muñoz F, et al. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001; 16: 1642-50.
Godfrey K, Walker K, Robinson S, et al. Neonatal bone mass: Influence of parental birth wieght, maternal smoking, body composition and activity during pregnancy. J Bone Miner Res 2001; 16: 1694-703.
More C, Bettembuk P, Bhattoa HP, Balogh A. The effects of pregnancy and lactation on bone mineral density. Osteoporosis Int 2001; 12: 732-7.
Langlois JA, Mussolino ME, Visser M, et al. Weight loss from maxium body weight among middle-aged and older wihite women and the risk of hip fracture. The NAHANES I epidemiological follow-up study. Osteoporosis Int 2001; 12: 763-8.
Grainge MJ, Coupland CAC, Cliffe SJ, et al. Reproductive menstrual and menopausal factors: Which are associated with bone mineral density in early postmenopausal women? Osteoporosis Int 2001; 12: 788-93.
Hubacher M, Wettstein A. Acceptance of hipo protectors for hip fracture prevention in nursing homes. Osteoporosis Int 2001;12(9):794-9.
Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001; 112: 385-90.
Kanis JA, Dawson A, Oden A, Johnell O, de Late C, Jonson B. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356-61.
Watts NB, Harris ST, Genant HK. Treatment of painful osteoporotic vertebral fractures with percutaneus vertebroplasty or kyphoplasty. Osteoporos Int 2001; 12: 429-31.
Van Staa TP, Leufkens HGM, Cooper C. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 2000; 27: 563-8.
Sato Y, Kaji M, Higuchi F, Yanagida I, Oishi K, Oizumi K. Changes in bone and calcium metabolism following hip fracture in elderly patients. Osteoporos Int 2001; 12. 445-9.
MacDonald HM, McGuuigan FA, New SA, Campbell MK, Golden MHN, Ralston SH, Reid DM. Col1a1 sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss. J Bone Miner Res 2001; 9: 1634-41.
Bajnok E, Takacs I, Vargha P, Speer G, Nagy Z, Lakatos P. Lack of association between inteleukin-1 receptor antagonist protein gene polymorphism and bone mineral desnity in hungarian postmenopausal women. Bone 2001; 27: 559-62.
Khastir G, Studd J, Holland N, Alaghband-Zadeh, Sims TJ, Bailey AJ. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporos Int 2001; 12: 465-70.
Thomas T, Burguera B, Melton LJ, Atkinson EJ, O´Fallon WM. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001; 29: 114-20.
Efstathiadou Z, Tsatsoulis A, Ioannidis JPA. Association of collagen Ia 1 Sp1 polymorphism with the risk of prevalent fractures: a meta-analysis. J Bone Miner Res 2001; 16: 1586-92.
Patel S, Kwan JTC, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 2001; 16: 1863-70.
Lauderdale DS, Thisted RA, Wen M, Favus MJ. Bone mineral density and fracture among prevalent kidney stone cases in the third national health and nutrition examination survey. J Bone Miner Res 2001; 16: 1893-8.
Johansson S, Melhus H. Vitamin A antagonizes calcium response to vitamin D in man. J Bone Miner Res 2001; 16: 1899-905.
Godfey K, Walker-Bone K, Robinson S, et al. Neonatal bone mass: Influence of parental birthweight, maternal smoking, body composition and activity during pregnancy. J Bone Miner Res 2001; 16: 1694-703.
Beck TJ, Stone KL, Oreskovic TL, et al. Effect of current and discontinued estrogen replacement therapy on hip structural geometry: The Study of Osteoporotic Fractures. J Bone Miner Res 2001; 16: 2103-10.
Giannini S, Dàngelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001; 16: 2111-7.
Venesmaa PK, Kroger HPJ, Miettinen HJA, et al. Alendronate reduces periprosthetic bone loss after uncemented total hip arthoplasty: a prospective randomized study. J Bone Miner Res 2001; 16: 2126-31.
Heiskanen JT, Froger H, Paakkonen M, et al. Bone mineral metabolism after total gastrectomy. Bone 2001; 28: 123-7.
Legrand E, Hedde C, Gallois Y, et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone 2001; 29: 990-5.
Taylos JC, Sterkel B, Utley M, et al. Opinions and experiences in general practice on osteoporosis prevention, diagnosis and management. Osteoporosis Int 2001; 12: 844-8.
Tosteson ANA, Jonsson B, Grima DT, et al. Challenges for model based economic evaluations of poostmenopausal osteoporosis. Osteoporosis Int 2001; 12: 849-57.
Buchs N, Helg C, Collao C, et al. Allogeneic bone marrow transplantation in associated with a preferential femoral neck bone loss. Osteoporosis Int 2001; 12: 880-6.
NOTICIAS
LA FUNDACIÓN HISPANA DE OSTEOPOROSIS Y ENFERMEDADES METABÓLICAS ÓSEAS
Convoca el IX PREMIO CIENTÍFICO FHOEMO 2002 de acuerdo con las siguientes BASES
1. Este Premio, con una dotación de 1.506,02 e, tiene como objetivo premiar al mejor trabajo sobre Osteoporosis y Enfermedades Metabólicas Óseas.
2. El trabajo, para la presente edición, deberá haber sido desarrollado en España o Iberoamérica y publicado durante el año 2000 en cualquier revista de habla hispana.
3. La fecha límite para la recepción de los trabajos será el 15 de enero de 2003.
4. El Jurado estará compuesto por cuatro miembros del Comité Científico de la FHOEMO, actuando como secretaria del Jurado, con voz pero sin voto, la Secretaria de la misma.
5. La decisión del Jurado será inapelable y el Premio podrá ser declarado desierto si, a juicio del Jurado, se estimase que los trabajos presentados no reúnen el nivel profesional médico y técnico adecuados.
6. La FHOEMO se reserva la disponibilidad del trabajo una vez publicado para su difusión, si lo considera oportuno. Los trabajos concursantes no serán devueltos a sus autores.
7. Los aspirantes aceptarán las presentes bases por el mero hecho de concurrir a esta convocatoria.
8. Las solicitudes se enviarán, junto con seis copias del trabajo objeto de consideración, a: Premio Científico PHOEMO. Gil de Santivañes, 6. 28001 Madrid.